Fundraise

Nova Anchora raises $23M for topical therapy to treat rare skin disease

What's the deal? Nova Anchora, a Boston-based biotech, has raised $23 million in an early-stage equity round led by Viking Global InvestorsDealroom has a profile for this one. Try Dealroom →. The syndicate included venture philanthropy backers DEBRA Research gGmbHDealroom has a profile for this one. Try Dealroom →, EB Research Partnership, the EB Medical Research Foundation, and Cure EBDealroom has a profile for this one. Try Dealroom →.

What's the endgame? The company is developing NvA-021, an investigational topical gel containing recombinant human type VII collagen (C7), the protein that holds the skin's protective layer intact. In dystrophic epidermolysis bullosa (DEB), a rare genetic disease, C7 is absent or faulty, meaning minor friction can cause blistering and open wounds.

The gel is designed for application to wounds during routine bandage changes, with storage at home and use by patients or caregivers.

What's the money for? Proceeds will fund scale-up manufacturing, investigational new drug (IND)-enabling studies, an IND submission to the Food and Drug Administration, and an initial clinical proof-of-concept study. The round includes an initial tranche plus capital committed against specified development milestones.

Why now? "Recent advances have changed what we can offer people living with DEB, but patients still face a substantial burden of wounds and daily care," said Peter Marinkovich, co-founder and chair of the scientific advisory board. The program builds on research first funded at Stanford University by EBRP.

What could go wrong? Nova Anchora is entering a competitive field. The FDA approved AbeonaDealroom has a profile for this one. Try Dealroom →'s gene-corrected skin graft Zevaskyn in 2025, and Krystal's topical gene therapy Vyjuvek offers an approved, redosable option. In late October, PelthosDealroom has a profile for this one. Try Dealroom → agreed to combine with Castle Creek around an investigational C7-producing cell therapy, with up to $300 million in contingent milestones.

NvA-021 remains preclinical, with no clinical results yet. Its differentiation on durability, safety, or ease of use is unproven.

The signal: Money keeps flowing into DEB despite two approved treatments, suggesting investors see room for a less invasive, home-based option — if the clinical data arrives.

Read more: business.theeveningleader.com

Image credit: Generated with Gemini

More top stories